Showing results (101-110 of 150) with videos related to
Sort By:
Pageof 15
Thoracic Cancer|July 19, 2019
Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysisJia Zhong, Qiwen Zheng, Tongtong An, et al.Thoracic Cancer|June 26, 2024
Women patients with small-cell lung cancer using immunotherapy in a real-world cohort achieved long-term survivalYuling He, Lingdong Kong, Xumeng Ji, et al.Frontiers in Oncology|May 12, 2020
Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER DatabaseYuyan Wang, Qiwen Zheng, Bo Jia, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 8, 2026
SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in ChinaShun Lu, Jian Fang, Yan Yu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2024
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL StudyShun Lu, Lin Wu, Qiming Wang, et al.Nutrients|October 14, 2023
Is Increasing Diet Diversity of Animal-Source Foods Related to Better Health-Related Quality of Life among Chinese Men and Women?Hui Jing, Yuxin Teng, Samuel Chacha, et al.JTO Clinical and Research Reports|October 18, 2021
Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407Ying Cheng, Li Zhang, Jie Hu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 3, 2020
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M MutationYuankai Shi, Shucai Zhang, Xingsheng Hu, et al.BMC Cancer|April 11, 2023
Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib studyXingsheng Hu, Xinge Cui, Ziping Wang, et al.The Lancet. Oncology|January 17, 2022
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trialCaicun Zhou, Ziping Wang, Yuping Sun, et al.Pageof 15